Revisiting the relevance of Hirano bodies in neurodegenerative diseases

Koji Yoshida1,2,3, Shelley L Forrest1,2,4,5, Shojiro Ichimata3

  • 1Department of Laboratory Medicine and Pathobiology and Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Insights

Hirano bodies (HBs) are pathological structures found in neurodegenerative diseases. Different HB morphologies are associated with specific conditions like Alzheimer's and Lewy body disease.

Area of Science:

  • Neuropathology
  • Neurodegenerative Diseases

Background:

  • Hirano bodies (HBs) are eosinophilic inclusions observed in the hippocampus, particularly in Alzheimer's disease (AD).
  • HBs exhibit distinct morphological phenotypes, traditionally described as rod-shaped.

Purpose of the Study:

  • To evaluate the prevalence and distribution of Hirano bodies (HBs) in Alzheimer's disease (AD) and other neurodegenerative conditions.
  • To characterize different morphological types of HBs and their association with specific diseases.

Main Methods:

  • A cross-sectional study analyzed 193 cases, including AD, Lewy body disease (LBD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and controls.
  • Systematic evaluation of HB prevalence, number, and morphology in the hippocampal CA1 region and stratum lacunosum (HBL).
  • Investigation of HBs across five additional hippocampal subregions.

Main Results:

  • Three HB morphologies were identified: classic rod-shaped (CHB), balloon-shaped (BHB), and newly described string-shaped (SHB).
  • CHB prevalence was increased in AD and related conditions; BHB in AD+LBD and PSP; SHB in AD+LBD, PSP, and argyrophilic grain disease.
  • HBLs were associated with MSA, while CHBs correlated with Braak NFT stage, BHBs with LBD/TDP-43 pathology, and SHBs with Braak NFT stage/PSP.

Conclusions:

  • Hirano bodies are not exclusive to AD but are associated with a spectrum of neurodegenerative diseases.
  • Distinct HB morphologies serve as potential pathological markers for differentiating various neurodegenerative conditions.
Abstract

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541